The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus ...
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...
Tuberculosis remains the number one cause of infectious mortality worldwide A candidate mRNA vaccine that boosts immunity ...
A recent study confirms that the 100-year-old BCG vaccine does not protect against COVID-19, challenging early assumptions ...
ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...
Discover how AI-based assays offer a promising approach to tailor treatment for high-risk non-muscle-invasive bladder cancer.
Among specific vaccines, Bacillus Calmette-Guerin (BCG) had a coverage of 96 per cent, Pentavalent (DPT+Hep-B+HiB) reached 95 ...
Despite TB’s staggering death toll, Motsoaledi noted that the disease does not receive the same level of public attention as ...
CG Oncology (NASDAQ:CGON – Get Free Report) is projected to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect CG Oncology to post earnings of ($0.37) ...
The MHRA will now begin assessing the marketing authorization application (MAA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with bacillus Calmette-Guérin (BCG) for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback